Gastrointestinal Cancer
Conference Coverage
Statins, but not aspirin, linked to lower pancreatic cancer risk
Key clinical point: Statin use was linked to lower odds of pancreatic ductal adenocarcinoma, while aspirin use was not. Major finding: Statin use...
Conference Coverage
Histologic examination of anastomotic stapler doughnuts may not yield clinical benefit
A multicenter of patients who had low anterior resection with stapled anastomosis for rectal cancer found no clinical or economic benefit in...
News
Novel drug shows preclinical success in pancreatic cancer
SAN DIEGO – Based on studies in mice, the signals are promising for Metavert, a new drug for pancreatic cancer.
Conference Coverage
Sponge-on-a-string could move Barrett’s screening from GI lab to primary care
SAN DIEGO – An inexpensive sponge-on-a-string esophageal biopsy, combined with methylated DNA analysis, discriminated Barrett’s esophagus from...
Conference Coverage
Colorectal cancer threatens younger people
Health care providers should be alert for symptoms of colorectal cancer in younger patients, and encourage screening if symptoms are present.
Conference Coverage
Methylated DNA markers hold promise for Lynch syndrome
Methylated DNA markers (MDMs) have several advantages that are helpful for Lynch syndrome.
Conference Coverage
Metabolic factors associated with pancreatic NETs
Conference Coverage
Race predicts poor outcomes in people with liver cancer
Race was the strongest predictor of outcome in patients with hepatocellular carcinoma.
Conference Coverage
Fecal bacteria plus FIT promising in diagnosis of colorectal cancer
SAN DIEGO – Researchers have identified a panel of four fecal bacteria that appear to identify colorectal cancer early.
Conference Coverage
Acid suppression appears to prevent cancer in Barrett’s esophagus
A large study suggests that use of PPIs and H2RAs reduces the risk of progressing to cancer in patients with Barrett’s esophagus.
News
Liquid biopsy–based test detects BRAF mutations
Key clinical point: Analysis of plasma-derived cfDNA can identify BRAF mutations as accurately as FFPE tumor sample analysis. Major finding:...